Synchron is a technology company.
Synchron has raised $315.0M across 3 funding rounds.
Synchron has raised $315.0M in total across 3 funding rounds.
Synchron is a neurotechnology company developing implantable brain-computer interfaces (BCIs) to restore digital control for people with paralysis and severe physical disabilities, such as those with ALS.[1][2][4][6] Its flagship product, the Stentrode—a minimally invasive endovascular BCI—allows users to control devices like computers, smartphones, and apps using only their thoughts, addressing unmet needs in neuromodulation by enabling hands-free tasks such as texting or scheduling appointments.[2][4][5][6] With 51-200 employees, revenue between $10M-$50M, and headquarters in Brooklyn, New York (with operations in Australia), Synchron serves patients, healthcare providers, and research institutions, showing growth through partnerships with NVIDIA, Apple, and recent launches like the Chiral AI model trained on neural data.[1][4]
Founded in 2012 by Tom Oxley, a neurointerventionalist, Synchron emerged from the need for less invasive alternatives to open-brain surgery for BCIs, inspired by endovascular stent procedures.[4][6] Oxley's background in medicine drove the innovation of the Stentrode, implanted via blood vessels to access the brain safely.[2][4] Early traction came from human trials starting around 2019, pivotal awards like the 2019 UNSW Eureka Prize, and FDA breakthrough designations, evolving from research prototypes to clinical-stage devices with global teams in the US and Australia.[1][4]
Synchron rides the exploding neurotechnology wave, where the BCI market grows amid rising paralysis cases (e.g., ALS, stroke) and AI advancements enabling precise neural decoding.[1][2] Timing aligns with FDA's push for investigational devices and Big Tech's BCI interest—showcased at NVIDIA GTC—positioning it ahead of rivals like Blackrock Neurotech or Paradromics via safer implantation.[1][2] Market forces like aging populations, AI integration in healthcare, and demand for assistive tech favor Synchron, influencing the ecosystem by pioneering scalable brain data access that could transform neuro-medicine, diagnostics, and human-AI interfaces.[1][3][6]
Synchron is primed for regulatory milestones (e.g., full FDA approval) and commercialization, expanding trials and Chiral applications to pharma/research while deepening tech giant partnerships.[1][4] Trends like AI-driven neural analytics and wearable-free BCIs will accelerate adoption, potentially evolving Synchron from medical device leader to foundational neurotech platform, unlocking brain data at scale for millions—cementing its role in overcoming human body limitations.[1][3][6]
Synchron has raised $315.0M in total across 3 funding rounds.
Synchron's investors include ARCH Venture Partners, Khosla Ventures, Presight Capital, PSG, Founders Fund, Future Ventures, Hercules Capital.
Synchron has raised $315.0M across 3 funding rounds. Most recently, it raised $200.0M Series D in November 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2025 | $200.0M Series D | ARCH Venture Partners, Khosla Ventures, Presight Capital, PSG | |
| Dec 1, 2022 | $75.0M Series C | ARCH Venture Partners, Khosla Ventures, Presight Capital, PSG | |
| Jun 1, 2021 | $40.0M Series B | Founders Fund, Future Ventures, Hercules Capital, Presight Capital, PSG |